At the news
? BULLISHIMPACT 7/10 8-K filed Feb 25, 2026 at 06:32 ET
United Therapeutics reported record full-year 2025 revenue of $3.18 billion, up 11% year-over-year, driven by strong performance from Tyvaso DPI and Orenitram. Net income increased to $1.33 billion, and the company maintained its share repurchase program with $2 billion in accelerated buybacks. Management reaffirmed expectations for durable double-digit revenue growth.
- Full-year 2025 revenue reached $3.18 billion, up 11% from $2.88 billion in 2024
- Tyvaso DPI revenue grew 25% to $1.29 billion, driven by patient growth and Medicare Part D benefit redesign
- Net income increased 12% to $1.33 billion, with diluted EPS of $27.86
- Company executed $2 billion in accelerated share repurchases ($1 billion in August 2025 and $1 billion in March 2024)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access